Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity

Author： Breitkreutz Iris   Anderson Kenneth C  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.4, Iss.7, 2008-07, pp. : 973-985

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

By  

Letters in Drug Design & Discovery, Vol. 1, Iss. 2, 2004-04 ,pp. : 135-136

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide in multiple myeloma

By García-Sanz Ramón  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide - most significant drug in decades for multiple myeloma?

By  

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma: An Overview of Clinical and Economic Information

By Messori Andrea  

PharmacoEconomics, Vol. 29, Iss. 4, 2011-04 ,pp. : 269-285

Adis International

Access to resources Recommend Favorite